Venture Capital

Bridge To Life Raises $110 Million To Scale FDA-Cleared VitaSmart Liver Perfusion System And Expand Organ Transplant Pipeline

By Amit Chowdhry ● Aug 20, 2026

Bridge to Life has completed $110 million in Series C equity and debt financing to accelerate the U.S. commercialization of its VitaSmart Hypothermic Oxygenated Perfusion System and advance a broader pipeline of organ preservation and viability technologies.

RockRose Risk Raises $12.5 Million Series A To Build Vertically Integrated Wildfire Insurance And Mitigation Platform

By Amit Chowdhry ● Aug 20, 2026

RockRose Risk has raised $12.5 million in Series A financing to expand its wildfire-focused insurance platform and evolve from a technology-enabled brokerage into a vertically integrated risk management business. The round was co-led by Crosslink Capital and Congruent Ventures, with participation from Nuveen Real Estate, which has more than $136 billion in commercial real estate holdings.

Ours Privacy Raises $15 Million Series A To Scale HIPAA-Compliant Healthcare Marketing Platform Across 200+ Organizations

By Amit Chowdhry ● Aug 20, 2026

Ours Privacy has raised $15 million in Series A funding to expand its privacy-first growth marketing and data infrastructure platform for healthcare organizations. The multiple-times-oversubscribed round was led by Lightbank and Health Velocity Capital, with participation from existing investors including Rock Health, Lakehouse, TMV, Switch Ventures, Starfire Ventures and GreyMatter.

Greenstone Biosciences Wins Breakthrough T1D Grant To Build Patient-Derived 3D Islet Platform With Multi-Omics

By Amit Chowdhry ● Aug 20, 2026

Greenstone Biosciences has received a Breakthrough T1D Industry Discovery and Development Partnership grant to develop a patient-derived islet cell platform aimed at improving understanding of insulin-producing beta cells in people with type 1 diabetes.

KaliVir Immunotherapeutics Raises $14 Million Series A Extension, Bringing Total Series A Funding To $25 Million

By Amit Chowdhry ● Aug 20, 2026

KaliVir Immunotherapeutics has raised a $14 million extension of its Series A financing to support continued clinical development of VET3-TGI, its lead oncolytic immunotherapy candidate for advanced solid tumors. The financing was led by Company K Partners, with participation from SV Investment and Flexus Partners. Existing investors, including affiliates of Nextrans and Quad Investment Management, also participated. The extension brings KaliVir's total Series A financing to $25 million.

Network Bio Launches With $50 Million Financing And $30+ Million AI Partnership To Build Disease-Specific Models

By Amit Chowdhry ● Aug 20, 2026

Network Bio has launched with $50 million in financing to build disease-specific artificial intelligence models trained on large-scale human tissue, blood, molecular and clinical datasets, as the biotechnology company seeks to apply AI to diagnostics, biomarker discovery and drug development. Investors include Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, JSL Health Capital and other life sciences and AI-focused funds.

Smack Raises $61 Million Series B, Bringing Total Funding Above $90 Million To Scale Tactical AI

By Amit Chowdhry ● Aug 20, 2026

Smack Technologies has raised $61 million in Series B financing to expand its domain-specific artificial intelligence technology for military decision-making, bringing the national security AI company's total capital raised to more than $90 million. Costanoa Ventures and First In led the round, with participation from Point72 Ventures, Geodesic Capital, Nomi Capital, Felicis, Scribble Ventures, Fortitude Ventures, Bloomberg Beta and Palumni VC.

Latin Metals And Minsur Agree Lacsha Copper Option With Up To $42.62 Million In Potential Cash Payments

By Amit Chowdhry ● Aug 20, 2026

Latin Metals has entered into a letter of intent with Minsur covering a potential acquisition of its wholly owned Lacsha Copper Project in Peru, with the structure offering Latin Metals up to $42.62 million in aggregate cash payments if all option and royalty buyback provisions are exercised. The companies plan to work toward definitive agreements within 90 days.

General Fusion Enters Public Markets With $150 Million As LM26 Heats Plasma To 8.4 Million Degrees

By Amit Chowdhry ● Aug 20, 2026

General Fusion Group has provided its first business update as a public company after becoming the first publicly listed fusion company through its July 2026 Nasdaq listing.

Saratoga Investment Prices $85 Million 8% Notes Offering To Redeem 6% Notes Due 2027

By Amit Chowdhry ● Aug 20, 2026

Saratoga Investment Corp. has priced an underwritten public offering of $85 million in aggregate principal amount of 8% unsecured notes due 2031, with proceeds expected to help redeem the company's outstanding 6% notes due 2027.